Proposition

3BP is commercializing three aspects of its technology platform:

  • Out-licensing of therapeutic and diagnostic product candidates after preclinical or clinical proof-of concept
  • Running collaborative peptidomimetics drug discovery programs from hit to preclinical candidate together with pharmaceutical partners
  • Custom development of affinity purification steps based on 3BP's peptidomimetic affinity ligand (PurAffinTM) technology for protein downstream processing
Experts in peptide drug discovery. Ingenuity from concept to clinical candidate.Experts in peptide drug discovery. Ingenuity from cExperts in peptide drug discovery. Ingenuity from concept to preclinics.